Aperio Group’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Aperio Group’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,742	Closed	-$46K	–	2922
2019 Q2	$46K	Buy	+3,742	New	+$43.2K	﹤0.01%	2551

Other funds holding FLXN

MVP

Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Aperio Group's FLXN Position: Q3 2019 in Review

Aperio Group sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2019, closing a stake of 3,742 shares — an estimated $46K sold.

Aperio Group first reported a position in FLXN in Q2 2019 and held it in 1 quarter. The position peaked at $46K in Q2 2019. 126 funds tracked by Wall St. Rank hold FLXN as of Q3 2019.

Aperio Group reported no remaining Flexion Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 3,742 Flexion Therapeutics, Inc. shares in Q3 2019, an estimated $46K.
Aperio Group first reported a position in Flexion Therapeutics, Inc. in Q2 2019 and held it in 1 quarter.
Aperio Group's Flexion Therapeutics, Inc. position peaked at $46K in Q2 2019.
126 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.